Catalio Capital Management LP Purchases Shares of 714,501 Ocular Therapeutix, Inc. $OCUL

Catalio Capital Management LP purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 714,501 shares of the biopharmaceutical company’s stock, valued at approximately $8,674,000. Ocular Therapeutix accounts for about 1.6% of Catalio Capital Management LP’s investment portfolio, making the stock its 26th largest holding. Catalio Capital Management LP owned 0.33% of Ocular Therapeutix at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Citigroup Inc. lifted its holdings in shares of Ocular Therapeutix by 574.4% during the 3rd quarter. Citigroup Inc. now owns 673,348 shares of the biopharmaceutical company’s stock worth $7,871,000 after acquiring an additional 573,504 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Ocular Therapeutix by 9.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,163,240 shares of the biopharmaceutical company’s stock worth $107,118,000 after acquiring an additional 771,065 shares during the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Ocular Therapeutix during the 3rd quarter worth $2,360,000. Avoro Capital Advisors LLC lifted its holdings in shares of Ocular Therapeutix by 38.5% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock worth $119,822,000 after acquiring an additional 2,850,000 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB bought a new stake in shares of Ocular Therapeutix during the 3rd quarter worth $2,361,000. 59.21% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the sale, the insider directly owned 2,597,170 shares of the company’s stock, valued at $21,296,794. The trade was a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 28,999 shares of company stock valued at $237,792 over the last ninety days. Insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock opened at $9.64 on Thursday. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $2.11 billion, a PE ratio of -6.60 and a beta of 0.89. The firm has a fifty day simple moving average of $8.95 and a two-hundred day simple moving average of $9.94. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.